Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 483

1.

Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.

Canaz E, Grabowski JP, Richter R, Braicu EI, Chekerov R, Sehouli J.

Gynecol Oncol. 2019 Jun 20. pii: S0090-8258(19)31327-7. doi: 10.1016/j.ygyno.2019.06.014. [Epub ahead of print]

PMID:
31230821
2.

Anxiety of myoma patients: results of standardized interviews with the State Trait Anxiety Inventory and the Kessler 10 questionnaire.

Knudsen NI, Richter R, Kentenich H, Sehouli J, David M.

J Psychosom Obstet Gynaecol. 2019 Jun 10:1-9. doi: 10.1080/0167482X.2019.1624951. [Epub ahead of print]

PMID:
31179813
3.

Lymphadenectomy in Advanced Ovarian Neoplasms. Reply.

Harter P, Sehouli J, du Bois A.

N Engl J Med. 2019 Jun 6;380(23):2274-2275. doi: 10.1056/NEJMc1904411. No abstract available.

PMID:
31167063
4.

Sialic Acid Linkage Analysis Refines the Diagnosis of Ovarian Cancer.

Dědová T, Braicu EI, Sehouli J, Blanchard V.

Front Oncol. 2019 Apr 11;9:261. doi: 10.3389/fonc.2019.00261. eCollection 2019.

5.

Interrelations of Sphingolipid and Lysophosphatidate Signaling with Immune System in Ovarian Cancer.

Meshcheryakova A, Svoboda M, Jaritz M, Mungenast F, Salzmann M, Pils D, Cacsire Castillo-Tong D, Hager G, Wolf A, Braicu EI, Sehouli J, Lambrechts S, Vergote I, Mahner S, Birner P, Zimmermann P, Brindley DN, Heinze G, Zeillinger R, Mechtcheriakova D.

Comput Struct Biotechnol J. 2019 Apr 10;17:537-560. doi: 10.1016/j.csbj.2019.04.004. eCollection 2019.

6.

Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study.

Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, Raspagliesi F, Sonke GS, Birrer M, Provencher DM, Sehouli J, Colombo N, González-Martín A, Oaknin A, Ottevanger PB, Rudaitis V, Katchar K, Wu H, Keefe S, Ruman J, Ledermann JA.

Ann Oncol. 2019 May 2. pii: mdz135. doi: 10.1093/annonc/mdz135. [Epub ahead of print]

PMID:
31046082
7.

A GCIG international survey: clinical practice patterns of sentinel lymph node biopsies in cervical cancer.

Vercellino GF, Erdemoglu E, Lichtenberg P, Muallem MZ, Richter R, Abu-Rustum NR, Plante M, Lécuru F, Greggi S, Monk BJ, Sagae S, Denkert C, Keller M, Alhakeem M, Hellriegel M, Dückelmann AM, Chiantera V, Sehouli J.

Arch Gynecol Obstet. 2019 Jul;300(1):191-199. doi: 10.1007/s00404-019-05164-2. Epub 2019 Apr 21.

PMID:
31006839
8.

Prognostic role of chemotherapy-induced nausea and vomiting in recurrent ovarian cancer patients: results of an individual participant data meta-analysis in 1213.

Woopen H, Richter R, Chekerov R, Inci G, Alavi S, Grabowski JP, Sehouli J.

Support Care Cancer. 2019 Apr 13. doi: 10.1007/s00520-019-04778-1. [Epub ahead of print]

PMID:
30980260
9.

Current practice and physicians' opinion about preoperative hair removal as a part of ERAS pathway implementation in gynecology and gynecology-oncology: a NOGGO-AGO survey of 148 gynecological departments in Germany.

Plett H, Ricciardi E, Bommert M, Veldink H, Traut A, Pietzner K, Zelal Muallem M, Sehouli J.

Arch Gynecol Obstet. 2019 Jun;299(6):1607-1618. doi: 10.1007/s00404-019-05132-w. Epub 2019 Apr 5.

PMID:
30953189
10.

Chronic Chlamydia infection in human organoids increases stemness and promotes age-dependent CpG methylation.

Kessler M, Hoffmann K, Fritsche K, Brinkmann V, Mollenkopf HJ, Thieck O, Teixeira da Costa AR, Braicu EI, Sehouli J, Mangler M, Berger H, Meyer TF.

Nat Commun. 2019 Mar 18;10(1):1194. doi: 10.1038/s41467-019-09144-7.

11.

Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines.

Yang Z, Guo F, Albers AE, Sehouli J, Kaufmann AM.

Biomed Pharmacother. 2019 May;113:108727. doi: 10.1016/j.biopha.2019.108727. Epub 2019 Mar 12.

12.

Patients' perspectives towards malignant ascites: results of a prospective observational trial regarding expectations, characteristics and quality of life-a study of the North-Eastern-German Society of Gynecological Oncology.

Armbrust R, Neeb C, Thuss-Patience P, Lüftner D, Pietzner K, Riess H, Oskay-Öczelik G, Richter R, Keller M, Sehouli J.

Arch Gynecol Obstet. 2019 May;299(5):1385-1389. doi: 10.1007/s00404-019-05071-6. Epub 2019 Mar 5.

PMID:
30834969
13.

A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms.

Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, Kim JW, Raspagliesi F, Lampe B, Aletti G, Meier W, Cibula D, Mustea A, Mahner S, Runnebaum IB, Schmalfeldt B, Burges A, Kimmig R, Scambia G, Greggi S, Hilpert F, Hasenburg A, Hillemanns P, Giorda G, von Leffern I, Schade-Brittinger C, Wagner U, du Bois A.

N Engl J Med. 2019 Feb 28;380(9):822-832. doi: 10.1056/NEJMoa1808424.

PMID:
30811909
14.

Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium.

Guan J, Darb-Esfahani S, Richter R, Taube ET, Ruscito I, Mahner S, Woelber L, Prieske K, Concin N, Vergote I, Van Nieuwenhuysen E, Achimas-Cadariu P, Glajzer J, Woopen H, Stanske M, Kulbe H, Denkert C, Sehouli J, Braicu EI.

J Cancer Res Clin Oncol. 2019 Apr;145(4):1063-1073. doi: 10.1007/s00432-019-02877-4. Epub 2019 Feb 27.

PMID:
30810838
15.

Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study.

Polterauer S, Schwameis R, Grimm C, Hillemanns P, Jückstock J, Hilpert F, de Gregorio N, Hasenburg A, Sehouli J, Fürst ST, Strauß HG, Baumann K, Thiel F, Mustea A, Harter P, Wimberger P, Kölbl H, Reinthaller A, Woelber L, Mahner S.

Gynecol Oncol. 2019 May;153(2):286-291. doi: 10.1016/j.ygyno.2019.02.007. Epub 2019 Feb 11.

PMID:
30760408
16.

A report on the Marrakech International Women's Cancer Days: dialogs and implications.

Nasser S, Berek J, Ullrich A, Giordano L, Sehouli J.

Int J Gynecol Cancer. 2019 Feb;29(2):417-421. doi: 10.1136/ijgc-2018-000059. Epub 2018 Dec 21.

PMID:
30718317
17.

Key regulator of cellular metabolism, estrogen-related receptor α, a new therapeutic target in endocrine-related gynecological tumor.

Liu G, Sun P, Dong B, Sehouli J.

Cancer Manag Res. 2018 Dec 12;10:6887-6895. doi: 10.2147/CMAR.S182466. eCollection 2018. Review.

18.

Arrangement of myofibroblastic and smooth muscle-like cells in superficial peritoneal endometriosis and a possible role of transforming growth factor beta 1 (TGFβ1) in myofibroblastic metaplasia.

Ibrahim MG, Sillem M, Plendl J, Taube ET, Schüring A, Götte M, Chiantera V, Sehouli J, Mechsner S.

Arch Gynecol Obstet. 2019 Feb;299(2):489-499. doi: 10.1007/s00404-018-4995-y. Epub 2018 Dec 7.

PMID:
30523440
19.

GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis.

Cabral-Marques O, Marques A, Giil LM, De Vito R, Rademacher J, Günther J, Lange T, Humrich JY, Klapa S, Schinke S, Schimke LF, Marschner G, Pitann S, Adler S, Dechend R, Müller DN, Braicu I, Sehouli J, Schulze-Forster K, Trippel T, Scheibenbogen C, Staff A, Mertens PR, Löbel M, Mastroianni J, Plattfaut C, Gieseler F, Dragun D, Engelhardt BE, Fernandez-Cabezudo MJ, Ochs HD, Al-Ramadi BK, Lamprecht P, Mueller A, Heidecke H, Riemekasten G.

Nat Commun. 2018 Dec 6;9(1):5224. doi: 10.1038/s41467-018-07598-9.

20.

Olaparib Desensitization in a Patient with Recurrent Peritoneal Cancer.

Grabowski JP, Sehouli J, Glajzer J, Worm M, Zuberbier T, Maurer M, Fluhr JW.

N Engl J Med. 2018 Nov 29;379(22):2176-2177. doi: 10.1056/NEJMc1810168. No abstract available. Erratum in: N Engl J Med. 2019 Apr 4;380(14):1386.

PMID:
30485775
21.

MALDI-Imaging for Classification of Epithelial Ovarian Cancer Histotypes from a Tissue Microarray Using Machine Learning Methods.

Klein O, Kanter F, Kulbe H, Jank P, Denkert C, Nebrich G, Schmitt WD, Wu Z, Kunze CA, Sehouli J, Darb-Esfahani S, Braicu I, Lellmann J, Thiele H, Taube ET.

Proteomics Clin Appl. 2019 Jan;13(1):e1700181. doi: 10.1002/prca.201700181. Epub 2018 Dec 14.

PMID:
30471200
22.

Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12.

Heitz F, Harter P, Åvall-Lundqvist E, Reuss A, Pautier P, Cormio G, Colombo N, Reinthaller A, Vergote I, Poveda A, Ottevanger PB, Hanker LC, Leminen A, Alexandre J, Canzler U, Sehouli J, Herrstedt J, Fiane B, Merger M, du Bois A.

Gynecol Oncol. 2019 Feb;152(2):235-242. doi: 10.1016/j.ygyno.2018.11.008. Epub 2018 Nov 20.

PMID:
30466805
23.

Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network.

Sehouli J, Braicu EI, Richter R, Denkert C, Jank P, Jurmeister PS, Kunze CA, Budczies J, Darb-Esfahani S, Schmitt WD, Traut A, Grabowski J, Taube ET, Plett H.

Hum Pathol. 2019 Mar;85:299-308. doi: 10.1016/j.humpath.2018.10.020. Epub 2018 Nov 11.

PMID:
30428389
24.

Establishment of a Mucin Secreting Cell Line Cx-03 from an Uterine Carcino Sarcoma.

Bücker R, Schaefer C, Gruber AD, Hoppe J, Lazzerini L, Barinoff J, Sehouli J, Cichon G.

Pharm Res. 2018 Nov 8;36(1):7. doi: 10.1007/s11095-018-2533-z.

PMID:
30411161
25.

What is the evidence for lymphadenectomy in presumed early ovarian cancer?

Schmalfeldt B, Brambs C, Burges A, El-Balat A, Emons G, Fink D, Fotopoulou C, Gropp-Meier M, Hanker LC, Harter P, Hasenburg A, Hauptmann S, Hilpert F, Kimmig R, Kommoss S, Kurzeder C, Mahner S, Marmé F, Mayr D, Meier W, Meinhold-Heerlein I, Mustea A, Ortmann O, Oskay-Özcelik G, Pfisterer J, Pölcher M, Runnebaum IB, Schröder W, Tanner B, Wagner U, Wimberger P, Sehouli J.

Arch Gynecol Obstet. 2019 Jan;299(1):1-5. doi: 10.1007/s00404-018-4945-8. No abstract available.

PMID:
30374648
26.

Mesothelin as a target for cervical cancer therapy.

Jöhrens K, Lazzerini L, Barinoff J, Sehouli J, Cichon G.

Arch Gynecol Obstet. 2019 Jan;299(1):211-216. doi: 10.1007/s00404-018-4933-z. Epub 2018 Oct 15.

PMID:
30324544
27.

Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.

Patel JN, Braicu I, Timms KM, Solimeno C, Tshiaba P, Reid J, Lanchbury JS, Darb-Esfahani S, Ganapathi MK, Sehouli J, Ganapathi RN.

Br J Cancer. 2018 Oct;119(9):1060-1066. doi: 10.1038/s41416-018-0268-6. Epub 2018 Oct 15.

PMID:
30318511
28.

Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism.

Niemi RJ, Braicu EI, Kulbe H, Koistinen KM, Sehouli J, Puistola U, Mäenpää JU, Hilvo M.

Br J Cancer. 2018 Oct;119(7):847-854. doi: 10.1038/s41416-018-0270-z. Epub 2018 Oct 8.

PMID:
30293997
29.

APOBEC3B protein expression and mRNA analyses in patients with high-grade serous ovarian carcinoma.

Rüder U, Denkert C, Kunze CA, Jank P, Lindner J, Jöhrens K, Kulbe H, Sehouli J, Dietel M, Braicu E, Darb-Esfahani S.

Histol Histopathol. 2019 Apr;34(4):405-417. doi: 10.14670/HH-18-050. Epub 2018 Oct 5.

PMID:
30289149
30.

Impact of Body Mass Index (BMI) on Chemotherapy-associated Toxicity in Ovarian Cancer Patients. A Pooled Analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) Databank on 1,213 Patients.

Grabowski JP, Richter R, Rittmeister H, Chekerov R, Woopen H, Sehouli J.

Anticancer Res. 2018 Oct;38(10):5853-5858. doi: 10.21873/anticanres.12927.

PMID:
30275210
31.

Is there a role for HIPEC in ovarian cancer?

Harter P, du Bois A, Sehouli J, Mahner S, Vergote I, Chiva L, Gonzalez-Martin A, Fotopoulou C.

Arch Gynecol Obstet. 2018 Nov;298(5):859-860. doi: 10.1007/s00404-018-4908-0.

PMID:
30232581
32.

Checkpoint-inhibition in ovarian cancer: rising star or just a dream?

Pietzner K, Nasser S, Alavi S, Darb-Esfahani S, Passler M, Muallem MZ, Sehouli J.

J Gynecol Oncol. 2018 Nov;29(6):e93. doi: 10.3802/jgo.2018.29.e93. Review.

33.

Potential role of the HOXD8 transcription factor in cisplatin resistance and tumour metastasis in advanced epithelial ovarian cancer.

Sun P, Song Y, Liu D, Liu G, Mao X, Dong B, Braicu EI, Sehouli J.

Sci Rep. 2018 Sep 7;8(1):13483. doi: 10.1038/s41598-018-31030-3.

34.

The genetic landscape of 87 ovarian germ cell tumors.

Van Nieuwenhuysen E, Busschaert P, Neven P, Han SN, Moerman P, Liontos M, Papaspirou M, Kupryjanczyk J, Hogdall C, Hogdall E, Oaknin A, Garcia A, Mahner S, Trillsch F, Cibula D, Heitz F, Concin N, Speiser P, Salvesen H, Sehouli J, Lambrechts D, Vergote I.

Gynecol Oncol. 2018 Oct;151(1):61-68. doi: 10.1016/j.ygyno.2018.08.013. Epub 2018 Aug 28.

PMID:
30170975
35.

Participation of elderly gynecological cancer patients in clinical trials.

Prieske K, Trillsch F, Oskay-Özcelik G, Chekerov R, Bleich C, Oliveira-Ferrer L, Grimm D, Kuerti S, Mueller V, Suling A, Schmalfeldt B, Sehouli J, Mahner S, Woelber L.

Arch Gynecol Obstet. 2018 Oct;298(4):797-804. doi: 10.1007/s00404-018-4886-2. Epub 2018 Aug 30.

PMID:
30167853
36.

Clinical Significance of Organic Anion Transporting Polypeptide Gene Expression in High-Grade Serous Ovarian Cancer.

Svoboda M, Mungenast F, Gleiss A, Vergote I, Vanderstichele A, Sehouli J, Braicu E, Mahner S, Jäger W, Mechtcheriakova D, Cacsire-Tong D, Zeillinger R, Thalhammer T, Pils D.

Front Pharmacol. 2018 Aug 7;9:842. doi: 10.3389/fphar.2018.00842. eCollection 2018.

37.

Novel endocrine therapeutic strategy in endometrial carcinoma targeting estrogen-related receptor α by XCT790 and siRNA.

Sun P, Mao X, Gao M, Huang M, Chen L, Ruan G, Huang W, Braicu EI, Sehouli J.

Cancer Manag Res. 2018 Aug 10;10:2521-2535. doi: 10.2147/CMAR.S168043. eCollection 2018.

38.

Safety and dose modification for patients receiving niraparib.

Berek JS, Matulonis UA, Peen U, Ghatage P, Mahner S, Redondo A, Lesoin A, Colombo N, Vergote I, Rosengarten O, Ledermann J, Pineda M, Ellard S, Sehouli J, Gonzalez-Martin A, Berton-Rigaud D, Madry R, Reinthaller A, Hazard S, Guo W, Mirza MR.

Ann Oncol. 2019 May 1;30(5):859. doi: 10.1093/annonc/mdy255. No abstract available.

PMID:
30107447
39.

Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Chekerov R, Hilpert F, Mahner S, El-Balat A, Harter P, De Gregorio N, Fridrich C, Markmann S, Potenberg J, Lorenz R, Oskay-Oezcelik G, Schmidt M, Krabisch P, Lueck HJ, Richter R, Braicu EI, du Bois A, Sehouli J; NOGGO; AGO TRIAS Investigators.

Lancet Oncol. 2018 Sep;19(9):1247-1258. doi: 10.1016/S1470-2045(18)30372-3. Epub 2018 Aug 9.

PMID:
30100379
40.

Clinical Outcome After Completion Surgery in Patients With Ovarian Cancer: The Charite Experience.

Babayeva A, Braicu EI, Grabowski JP, Gasimli K, Richter R, Muallem MZ, Sehouli J.

Int J Gynecol Cancer. 2018 Oct;28(8):1491-1497. doi: 10.1097/IGC.0000000000001328.

PMID:
30095708
41.

Preoperative CA-125 Value as a Predictive Factor for Postoperative Outcome in First Relapse of Platinum-sensitive Serous Ovarian Cancer.

Parashkevova A, Sehouli J, Richter R, Dimitrova D, Braicu EI, Muallem MZ.

Anticancer Res. 2018 Aug;38(8):4865-4870. doi: 10.21873/anticanres.12799.

PMID:
30061261
42.

Development of a Questionnaire for Monitoring Risk Factors for Chemotherapy-induced Nausea and Vomiting - A NOGGO Pilot Study.

Rittmeister H, Oskay-Özcelik G, Richter R, Sehouli J, Grabowski JP.

Anticancer Res. 2018 Aug;38(8):4859-4864. doi: 10.21873/anticanres.12798.

PMID:
30061260
43.

Preoperative Evaluation of Myometrial Invasion in Endometrial Carcinoma: Prospective Intra-individual Comparison of Magnetic Resonance Volumetry, Diffusion-weighted and Dynamic Contrast-enhanced Magnetic Resonance Imaging.

Thieme SF, Collettini F, Sehouli J, Biocca L, Lella A, Wagner M, Almuheimid J, Plett H, Muallem MZ.

Anticancer Res. 2018 Aug;38(8):4813-4817. doi: 10.21873/anticanres.12791.

PMID:
30061253
44.

Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.

Oza AM, Matulonis UA, Malander S, Hudgens S, Sehouli J, Del Campo JM, Berton-Rigaud D, Banerjee S, Scambia G, Berek JS, Lund B, Tinker AV, Hilpert F, Vázquez IP, D'Hondt V, Benigno B, Provencher D, Buscema J, Agarwal S, Mirza MR.

Lancet Oncol. 2018 Aug;19(8):1117-1125. doi: 10.1016/S1470-2045(18)30333-4. Epub 2018 Jul 17.

PMID:
30026000
45.

Morphology and tumour-infiltrating lymphocytes in high-stage, high-grade serous ovarian carcinoma correlated with long-term survival.

Darb-Esfahani S, Kolaschinski I, Trillsch F, Mahner S, Concin N, Vergote I, Van Nieuwenhuysen E, Achimas-Cadariu P, Glajzer J, Woopen H, Wienert S, Taube ET, Stanske M, Kulbe H, Denkert C, Sehouli J, Braicu EI.

Histopathology. 2018 Dec;73(6):1002-1012. doi: 10.1111/his.13711. Epub 2018 Oct 7.

PMID:
30007074
46.

Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).

Ruscito I, Cacsire Castillo-Tong D, Vergote I, Ignat I, Stanske M, Vanderstichele A, Glajzer J, Kulbe H, Trillsch F, Mustea A, Kreuzinger C, Benedetti Panici P, Gourley C, Gabra H, Nuti M, Taube ET, Kessler M, Sehouli J, Darb-Esfahani S, Braicu EI.

Br J Cancer. 2018 Aug;119(3):330-338. doi: 10.1038/s41416-018-0157-z. Epub 2018 Jun 29.

47.

HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer?

Fotopoulou C, Sehouli J, Mahner S, Harter P, Van Nieuwenhuysen E, Gonzalez-Martin A, Vergote I, Chiva L, Du Bois A.

Ann Oncol. 2018 Aug 1;29(8):1610-1613. doi: 10.1093/annonc/mdy198. No abstract available.

PMID:
29873689
48.

The Role of PAR1 Autoantibodies in Patients with Primary Epithelial Ovarian Cancer.

Kreienbring K, Franz A, Richter R, Dragun D, Heidecke H, Müller D, Mentze M, Dechend R, Sehouli J, Braicu EI.

Anticancer Res. 2018 Jun;38(6):3619-3625. doi: 10.21873/anticanres.12636.

PMID:
29848718
49.

Safety and dose modification for patients receiving niraparib.

Berek JS, Matulonis UA, Peen U, Ghatage P, Mahner S, Redondo A, Lesoin A, Colombo N, Vergote I, Rosengarten O, Ledermann J, Pineda M, Ellard S, Sehouli J, Gonzalez-Martin A, Berton-Rigaud D, Madry R, Reinthaller A, Hazard S, Guo W, Mirza MR.

Ann Oncol. 2018 Aug 1;29(8):1784-1792. doi: 10.1093/annonc/mdy181.

PMID:
29767688
50.

The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis.

Ruscito I, Darb-Esfahani S, Kulbe H, Bellati F, Zizzari IG, Rahimi Koshkaki H, Napoletano C, Caserta D, Rughetti A, Kessler M, Sehouli J, Nuti M, Braicu EI.

Gynecol Oncol. 2018 Jul;150(1):151-157. doi: 10.1016/j.ygyno.2018.05.006. Epub 2018 May 10.

PMID:
29753392

Supplemental Content

Loading ...
Support Center